|
|
SPEAKERS |
|
| |
|
 |
| Randy W. Schekman |
| Keynote Speaker |
|
|
Nobel laureate, the 2013 Nobel Prize for Physiology or Medicine
Professor of Molecular and Cell Biology, University of California, Berkeley |
| |
| Randy Wayne Schekman is a Nobel Prize-winning professor in Cell Biology at the University of California, Berkeley. He was the former editor-in-chief of Proceedings at the National Academy of Sciences. Dr. Schekman was elected to that prestigious academy in 1992. In 2011 Dr. Schekman was chosen as the editor of eLife, a new, high profile, and open access journal published by the Howard Hughes Medical Institute, the Max Planck Society and the Wellcome Trust. |
| |
| Dr. Schekman shared the 2013 Nobel Prize for Physiology or Medicine with James Rothman and Thomas C. Sudhof for their ground breaking work on cell membrane vesicle trafficking. |
|
|
|
|
|
 |
| Kevin Chen |
|
|
| Managing Partner, Biotrack Capital |
| |
| Kevin (Penghui) Chen is Managing Partner of Biotrack Capital. Prior to his current role, he was partner at Sequoia Capital, responsible for healthcare investment. Before Sequoia Capital, Mr. Chen served as head and managing director of Everbright Healthcare. He led investment in many leading healthcare companies in China including BGI, Amcare, Betta Pharmaceuticals Inc, JIDA Pharmaceuticals Inc, Yuwell Medical, Zai Lab, Medtrum Medical, STP, Bai Yang Pharmaceuticals, Forerunner Medical, Guahao, etc. Before Everbright, he worked at ShangPharma, a leading China CRO company, first as COO & CFO between 2008 and 2010, and later as President in 2011. He took the company public at NYSE in 2010. Prior to ShangPharma, Mr. Chen was a vice president at CITIC Capital, responsible for healthcare and consumer industry. Before CITIC Capital, he held executive positions at BD & Corporate Investment at fortune 500 companies. Mr. Chen also worked as research scientist at Ligand Pharmaceuticals (Nasdaq: LGND) in San Diego, California. |
| |
| Mr. Chen holds a bachelor’s degree in chemistry from Nanjing University, a master’s degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University. |
|
|
|
|
|
 |
| Michael Chan |
|
|
|
| Sr. VP, Hong Kong Exchanges and Clearing Ltd. ("HKEX") |
| |
| Mr. Michael Chan heads the international issuer marketing team at the HKEX as the Senior Vice President of the Market Development Division. He is mainly focused on market development work promoting the Hong Kong listing platform and origination work attracting international companies to list in Hong Kong. In addition to leading the marketing efforts globally and working closely with prospects and constituents, Mr. Chan often speaks and serves as panelist and keynote speaker at major conferences and events locally and internationally. Before his current role, Mr. Chan had worked at the Listing Division of HKEX for eight years covering areas of compliance, corporate governance, regulatory and IPO-related matters.
Prior to joining HKEX, Mr. Chan had worked at various financial institutions in corporate finance and business development. He has more than 17 years of experience in financial services and regulatory work. |
|
|
|
|
|
 |
| Yingying Chen |
|
|
|
| Executive Director, GF Investments (Hong Kong) Company Limited |
| |
| Dr. Chen is a director on the board of GF Investments (Hong Kong) Company Limited. Dr. Chen has extensive investment and investment banking
experience, as well as rich industry experience in healthcare sector. Previously Dr. Chen was a research scientist with Pfizer global R&D center in Connecticut. She later joined UBS New York in the global healthcare investment banking group. Dr. Chen has also worked at Deutsche Bank and RBS in Hong Kong. |
|
|
|
|
|
 |
| Ted Driscoll |
|
|
| Managing Director, DigitalDX Ventures |
| |
| Ted Driscoll is Managing Director at a new venture fund, DigitalDx Ventures, whose focus is on Diagnostics in a Big-Data and Personalized Medicine World. Previously he was a Partner at Decheng Capital, and a Partner at Claremont Creek Ventures leading Digital Healthcare. He led the first investment in Natera (IPOed 2015), AssureX (acquired by Myriad Genetics for $410M) and GeneWeave (acquired by Roche for $425M). Prior to entering venture capital, he was an early leader/founder of five startups. His first startup, International Imaging Systems, built the first Digital Subtractive Angiography machines. He then led the team at Identix that pioneered the first digital fingerprint recognition, now used in the iPhone. Identix IPOed in 1984. He then joined Diasonics where he led the team that created the world’s first MRI scanners. He was then named Division President of a spinoff from Diasonics named Focus Surgery that pioneered noninvasive HIFU ablation surgery. This company IPOed in 1992. His last startup was Be Here Technologies, a 360degree imaging company, which was purchased by and incorporated into Google Streetview. |
| |
| Dr. Driscoll graduated from Stanford University with a PhD in Digital Imaging, and previously received a Master’s in Computer Graphics from Harvard, and a BA from the University of Pennsylvania. |
|
|
|
|
|
 |
| Samantha Du |
|
|
| Chairwoman and CEO, Zai Lab |
| |
| Dr. Du began her career with Pfizer in the US where she was responsible for the company's global metabolic licensing program and was also involved in the development of multiple early and late stage products, including two global blockbusters. She achieved her first success as an entrepreneur by founding Hutchison MediPharma (HMP), bringing five category 1.1 drugs into clinical trials. She has demonstrated strong capability of establishing partnerships with multinational companies such as AstraZeneca, J&J, Lilly, Merck Serono and Nestle. Dr. Du later joined Sequoia Capital as head of healthcare investments for China, making significant returns to the fund during her two-year tenure. |
| |
| Dr. Du founded Zai in 2014 with the goal of bringing innovative transformative medicines to China and creating a globally recognized biopharmaceutical leader. In 2017, Dr. Du successfully took Zai public on the NASDAQ. |
|
|
|
|
|
 |
| Doug Fisher |
|
|
|
| Partner, InterWest Partners |
| |
| Mr. Fisher joined InterWest's healthcare team in 2009, focusing on biopharmaceutical, diagnostic and medical device investments, and portfolio company support. He is a board member of Gynesonics, Indi Molecular, Obalon Therapeutics (OBLN), and QuatRx. Mr. Fisher is also actively involved in InterWest's investments in Benvenue, Integrated Diagnostics, PMV Pharma, Potenza Theraputics, and Sera Prognostics (where he serves as the Chief Business Officer). |
|
| Prior to joining InterWest, Mr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix (Acquired by Biogen Idec). Prior to joining New Leaf, Mr. Fisher was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group. |
|
| Mr. Fisher received an AB in economics with honors and distinction, and a BS in biology with distinction, from Stanford University, where he graduated Phi Beta Kappa. He has an MD from the University of Pennsylvania and an MBA from Wharton, where he graduated with honors as a Siebel Scholar and Palmer Scholar. |
|
|
|
|
|
 |
| David Flores |
|
|
| Co-Founder, President & CEO, BioCentury |
| |
| Mr. Flores has devoted more than 25 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. Mr. Flores is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, Mr. Flores and BioCentury Co-Founder & Chairman Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury's ongoing contributions to the industry. |
| |
| |
|
|
|
|
|
 |
| Julie Papanek Grant |
|
|
| Partner, Canaan |
| |
| As Partner of Canaan, Ms. Grant brings deep operational experience to her biopharma and digital health investments, having previously worked at Genentech across development and commercial divisions. She serves on the board of the Biden Cancer Initiative and co-chairs Planned Parenthood NorCal’s IT Advisory Board. In 2017, Ms. Grant was named one of Silicon Valley Business Times’ 40 Under 40. |
| |
| Ms. Grant holds an MBA from Stanford University, an MPhil. in BioScience Enterprise from Cambridge and a BS in Molecular Biophysics and Biochemistry from Yale University. |
| |
| Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas. While we love speedy success, we are acutely aware that greatness comes in many forms and at different times. That is why we are not afraid to break the mold to bring something spectacular to life. |
|
|
|
|
|
 |
| Hongjie Hu |
|
|
| Investment Director, Temasek |
| |
| Mr. Hu is Investment Director at Temasek, an investment company headquartered in Singapore with a multinational staff of 630 people. The company’s portfolio is S$275 billion and the company is focused primarily in Asia and Singapore. Starting March 9, 2017, Mr. Hu has also been a Director at CardioDx, Inc. |
| |
| Mr. Hu previously worked at Crosslink Capital, Inc. (Venture Capital), H.I.G. Capital LLC (Private Equity), and Tradenable, Inc. |
| |
| Mr. Hu received his BS in Electrical Engineering and MS in Engineering Management from Stanford University and an MBA from Harvard Business School. |
|
|
|
|
|
 |
| Patrick Heron |
|
|
| Managing General Partner, Frazier Healthcare Partners |
| |
| Mr. Heron is a Managing General Partner of Frazier’s Life Sciences team. He joined the firm in 1999 and opened Frazier’s Menlo Park office in 2003. Throughout his 12 years as a General Partner, Mr. Heron has led or co-led investments across nearly 20 companies. |
|
| Mr. Heron has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage anti-infectives companies to >$100M commercial-stage dermatology companies. Mr. Heron has also been active in company formation around both early- and later-stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including Tobira Therapeutics (acquired by Allergan), Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), MedPointe (acquired by Meda), and Collegium (NASDAQ: COLL). He currently serves on the boards of Imago BioSciences, Iterum Therapeutics, Silvergate Pharmaceuticals, SutroVax and Zavante Therapeutics. |
|
| Prior to joining Frazier, Mr. Heron helped develop McKinsey & Company's West Coast biotechnology consulting practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization. |
|
| Mr. Heron received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar. |
|
|
|
|
|
 |
| James Huang |
|
|
| Managing Partner, KPCB China |
| |
| James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Mr. Huang has made more than 15 investments in China since 2007. Before coming to KPCB China, Mr. Huang was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, he led numerous investments in China. Prior to joining Vivo in 2007, Mr. Huang was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, Mr. Huang held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp (acquired by Johnson & Johnson). |
|
| Mr. Huang is Chairman of Board at Kindstar Global, JHL Biotech and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, XW Laboratory and Omni Pharmaceuticals.
He received an MBA from Stanford University and a BS in chemical engineering from the University of California, Berkeley. He was born in Taipei, Taiwan.
|
|
|
|
|
|
 |
| Alexis Ji |
|
|
| Partner, Illumina Ventures |
| |
| Alexis Ji brings 12 years of experience in research and venture investment in the genomics and pharmaceutical industries. At Illumina Ventures, Ms. Ji focuses on investing in early-stage genomics technology platforms and applications in life science tools, diagnostics, therapeutics, and digital health. |
| |
| Prior to Illumina Ventures, Ms. Ji was a principal at WuXi Apptec Corporate Venture Fund and then WuXi Healthcare Ventures, a U.S.-China cross-border life science venture capital firm. She was instrumental in investments in Twist Bioscience, 23andme, Juno Therapeutics, Syros Pharmaceuticals, Unity Biotechnology, Vivace Therapeutics, Medeor Therapeutics, Ideaya Therapeutics, and Lumo Bodytech. Before joining WuXi, Ms. Ji was a venture investment consultant at ARCH Venture Partners. |
| |
| Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides most of our capital and access to the expertise and vision of the world's leading genomics solutions provider. |
|
|
|
|
|
 |
| Nisa Leung |
|
|
| Managing Partner, Qiming Ventures Partners |
| |
| Nisa Leung leads Qiming’s health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages five USD funds and four RMB funds with over USD 2.7 billion in assets and investment in over 220 companies. Prior to joining Qiming, Nisa was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone) and U-Systems (acquired by GE Healthcare). Nisa also worked as
Venture Partner for PacRim Ventures, and Softbank/Mobius Venture Capital. |
|
| Ms. Leung was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology and Berry Genomics (SZSE:000710). Her other investments include Acea Biosciences, Aeonmed Medical, Alltech Medical, CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, VR Medical, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen and New Horizon Bio. |
|
| Ms. Leung earned her MBA from Stanford University and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School. |
|
|
|
|
|
 |
| Yanhong Lin |
|
|
| Founder and Managing Partner, CTIC Capital |
| |
| Yanhong Lin is the Founder and Managing Partner at CTIC Capital. CTIC Capital provides investment banking services to companies in the field of Healthcare, IT and Energy. Yanhong and her team have successfully raised funding for US medical device companies and high tech companies. |
|
| Yanhong has close ties to venture capital firms in both Silicon Valley and Boston. She has established herself as a trusted advisor to VCs and entrepreneurs. Her clients are portfolio companies of top US VCs like General Catalyst, Khosla Venture, Prospect Venture, NEA and Third Rock. Her Chinese clients include top public traded Chinese companies. |
|
| Yanhong Lin has over 20 years of work experiences with Fortune 100 companies in the high tech and energy industries (Sun Microsystems, HP/Agilent and Amoco (now BP). Prior to founding CTIC Capital, she led the Corporate Financial Planning and Analysis team at Sun Microsystems (a $12 billion revenue company) with responsibilities of company’s forecast and P&L analysis. |
|
| Yanhong is a committee member of MIT Club of Northern California Energy and Environment, which was awarded the 2016 MIT Great Dome Award (is the highest honor that the MIT Alumni Association bestows upon any of its organizations). She is also an advisor to the Stanford Precourt Institute for Energy and successfully helped Chinese companies get engaged with Stanford. Yanhong was also served as Chair of the VC Taskforce China SIG (Special Interest Group). |
|
| Yanhong was born in Shanghai and grew up in Nanjing. She received BA from Western Illinois University in 1991 and her MBA from University of Illinois at Champaign-Urbana in 1993. She lives with her husband and two Children in Palo Alto, California. She enjoys skiing, traveling and spinning/biking. |
|
|
|
|
|
 |
| Derek Liu |
|
|
| Partner-Elect, Mergers & Acquisitions, WSRG |
| |
| Derek Liu is a partner-elect in Wilson Sonsini Goodrich & Rosati's mergers and acquisitions practice, where he focuses primarily on the technology and life sciences industries. Derek's transactional experience includes public and private company mergers, acquisitions, and divestitures; tender and exchange offers; joint ventures; minority investments; and other strategic corporate transactions, representing both strategic and private equity clients. Since joining the firm in 2013, Derek has signed transactions with an aggregate value of more than $38 billion. |
|
| In addition to M&A, Derek has significant capital markets and financing experience, having assisted clients with initial and secondary offerings, debt offerings, leverage recapitalizations, and exchange offers. He also has experience advising clients on corporate governance matters. |
|
|
|
|
|
 |
| Hongbo Lu |
|
|
| Partner, Lilly Asia Ventures |
| |
| Dr. Hongbo Lu is a partner at Lilly Asia Ventures, a healthcare-focused investment firm with over USD$1.2 billion AUM. She has over 15 years of investment and operational experience in healthcare industry, including her tenures at OrbiMed, Piper Jaffray & Co. and life science start-up Zyomyx. Prior to Lilly Asia, Dr. Lu was with OrbiMed Advisors, serving as its Managing Director in Asia, responsible for over $500m public equity investment portfolio in emerging markets. She also led a few private equity investments in OrbiMed. Dr. Lu served as board of directors of private and public companies. |
| |
| Dr. Lu received a Ph.D. in Bio Engineering from the University of Washington, an MBA from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China. |
|
|
|
|
|
 |
| Xiaobo Lu |
|
|
| Partner, Sequoia Capital China |
| |
| Before joining Sequoia Capital China, Mr. Lu served as a healthcare partner at Shenzhen Co-Win Venture Capital Investment Limited, focusing on healthcare investment. During his seven years in Co-Win Venture Capital, he led over 30 healthcare investments, including: BGI (SZSE:300676), Betta Pharmaceuticals (SZSE:300558), Jingfeng Pharmaceuticals (SZSE:000908), Konruns Pharmaceuticals (listing applications submitted), Chipscreen, Innovent, Zhongankang (acquired and gone private), etc. Prior to Co-Win Venture Capital, Mr. Lu had 15 years of experience in pharmaceutical sales and marketing. He worked in China Resource Sanjiu for almost ten years. |
|
| Mr. Lu received a bachelor’s degree in biochemistry engineering from Zhejiang University and an MBA degree from Tsinghua University. |
|
|
|
|
|
 |
| Hai Mi |
|
|
|
| Founding Managing Partner, Panacea Venture |
| |
| Dr. Hai Mi is the founding managing partner of Panacea Venture, a venture investment firm focusing on early-stage life science company investment. He is also a partner of KPCB China. |
|
| Prior to joining KPCB China, Dr. Mi was a partner at DT Capital responsible for investment in life science, healthcare and other related fields. Previously, he was the Venture Partner of SB China Venture Capital and his investment transactions included BGI, SyMap Medical and Precise Light Surgical. He also worked as Senior Director of Strategic Planning and Vice President of Corporate Communications at WuXi Apptec. Dr. Mi once served as the Independent Board Director and Audit Committee Chairman of Chemspec International. Earlier, he worked as a business consultant and a research scientist at Pfizer in the US. |
|
| Dr. Mi received his Ph.D. in organic chemistry from New York University, an MBA from the University of Chicago Booth School of Business, and a B.S. in material science from Fudan University in Shanghai. |
|
|
|
|
|
 |
| Amy Schulman |
|
|
| Entrepreneur Partner, Polaris Partners & Partner, LSP Fund |
| |
| Amy Schulman is an Entrepreneur Partner focused on funding and founding companies in the healthcare sector. Upon joining Polaris in 2015, she assumed the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company acquired by Eagle Pharmaceuticals (NASDAQ: EGRX) in November 2016. In July 2015, Ms. Schulman co-founded Lyndra, where she was CEO and in 2017 became CEO of Olivo Laboratories, both Polaris-backed companies. Also on behalf of Polaris, she serves as the Executive Chair of SQZ Biotech and Suono Bio and is director of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Ironwood Pharmaceuticals (NASDAQ: IRWD). In addition, Ms. Schulman serves as a director of Blue Buffalo (NASDAQ: BUFF) and the Whitehead Institute. |
|
| Prior to these roles, Ms. Schulman was responsible for leading Pfizer Inc.’s (NASDAQ: PFE) $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum, and Chapstick. She also served concurrently as Executive Vice President and General Counsel of Pfizer Inc. Previously at Pfizer, Ms. Schulman was SVP, President & General Manager of the infant formula and nutrition business where she was instrumental in the unit’s sale to Nestle for $11.85 billion in 2012. Before joining Pfizer, Ms. Schulman was a Partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, built and led the international law firm’s mass tort and class-action practice. |
|
| Ms. Schulman is the recipient of numerous awards and distinctions including: Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, Fortune Magazine’s 2013 50 Most Powerful Women in Business, The American Lawyer’s 2013 Top 50 Innovators, and The National Law Journal’s 2013 100 Most Influential Lawyers in America. She is a member of Harvard Business School’s Faculty where she serves as a Senior Lecturer and teaches legal and corporate accountability. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989. |
|
|
|
|
|
 |
| Christopher Shen |
|
|
| Managing Partner, Qiming Venture Partners |
| |
| Dr. Shen specializes in investments in biopharmaceutical and medical device companies. Prior to joining Qiming, Dr. Shen was a Managing Director and head of U.S. healthcare investing at Vertex Ventures Healthcare. Previously, he worked at Essex Woodlands Health Ventures, a healthcare-focused venture capital and private equity firm, and New Enterprise Associates, once the world’s largest VC firm. Earlier, Dr. Shen worked as Senior Design Engineer at Guidant Corporation's Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. He also worked as a Design Engineer for Pfizer, Inc.’s Strategic Innovation Group, an internal medical technology incubator in Japan. |
| |
| Dr. Shen is the U.S. Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He has nine issued patents and several pending patents in the fields of interventional neuroradiology and interventional cardiology. |
| |
| Dr. Shen received his MD, MBA, and Master of Biomechanical Engineering from the Stanford University. |
|
|
|
|
|
 |
| Alvin Syh |
|
|
| CEO, Buchang Asset Management; General Manager, Anrich Capital Asia |
| |
| Mr. Syh focuses on healthcare industry investments and managing assets of family offices. He is on the board of directors in a few biotech companies. Mr. Syh currently manages several well-known family offices, leading and implementing a full-spectrum of strategies in across sectors, stages, and regions including the US, EU, Israel and Asia. The global portfolio he has worked on with success covers more than 80 investment funds and more than 280 direct investment portfolio companies. |
|
| Buchang Asset Management is a private investment arm of Buchang Pharma, a leading China-based company principally engaged in research, development, manufacturing and distribution of Chinese patented medicines. Buchang Pharma’s current market cap is USD $7.8 billion. |
|
|
|
|
|
 |
| Khoon Jin Tan |
|
|
| Partner, Corporate, WSGR |
| |
| Khoon Jin (KJ) Tan is a partner in the Greater China practice at Wilson Sonsini Goodrich & Rosati. With extensive experience in advising clients in Hong Kong, KJ focuses his practice on general corporate, corporate finance, and commercial transactions. |
|
| Prior to joining the firm, KJ was managing director of an international investment bank in Hong Kong, where he served in the firm's China team. He was heavily involved both in the offering execution processes, including the supervision of external lawyers, and in business development and marketing. Among many other high-profile deals, KJ executed Huaneng Renewables' $850 million IPO, Agriculture Bank of China's $22.1 billion IPO, and China Railway Construction's $2.3 billion IPO. |
|
| Earlier in his career, KJ worked at a leading international firm's London, Hong Kong, Beijing, Jakarta, and Singapore offices, where he was involved in numerous IPOs and other corporate finance-related transactions. In addition, he advised clients on a wide variety of general corporate and commercial matters, including mergers and acquisitions, restructurings, and financing arrangements. |
|
| KJ is a fluent English and Mandarin speaker. He also speaks Cantonese and a few other Chinese dialects. |
|
|
|
|
|
 |
| Barry Taylor |
|
|
| Partner, Corporate, WSRG |
| |
| Barry Taylor is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati with 35 years of experience as a corporate and securities attorney and investment professional. |
|
| From 2000 to 2010, Barry was a managing director in the technology, media, and telecom group of Warburg Pincus, a global private equity firm. He served as the head of the firm's Silicon Valley office from 2000 to 2008. While at Warburg, Barry worked on investments in the United States, India, and China, and represented the firm on the boards of six portfolio companies. |
|
| Prior to joining Warburg Pincus, Barry was a senior corporate and securities partner at Wilson Sonsini Goodrich & Rosati for more than 16 years. During this time, he worked on numerous public financings as both issuers' and underwriters' counsel, and served as public securities counsel on disclosure, reporting, and proxy matters. This included representing 28 companies on their initial public offerings and underwriters on 40 initial public offerings. He also represented companies and investors in numerous private financings of preferred stock, convertible debt, and bridge loans with warrants. In addition, Barry negotiated and structured merger and acquisition transactions for both public and private companies. His clients included companies in a variety of sectors, including software, clean technology, healthcare, biotechnology, Internet, communications, and semiconductors. |
|
| Earlier in his career, Barry practiced with Pillsbury Madison & Sutro (now Pillsbury Winthrop Shaw Pittman) from 1975 to 1984, first as a litigator and then as a corporate and securities attorney. |
|
|
|
|
|
 |
| Karen Wong |
|
|
| Partner, Intellectual Property, WSGR |
| |
| Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom-to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs. |
|
| Concentrating on cutting-edge biotechnology, Karen focuses her multidisciplinary practice on a combination of molecular biology, optical physics, chemical engineering, pharmacology, molecular diagnostics, and cellular physiology. She has developed technical expertise in DNA-sequencing techniques and instruments, antibody engineering and design, biofuels, drug delivery systems, gene therapies, cancer treatments, and point-of-care diagnostic tools. |
|
| Prior to practicing law, Karen conducted doctoral and postdoctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology. |
|
| Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese. |
|
|
|
|
|
 |
| Jerry Xiao |
|
|
| CEO, Hermed Capital |
| |
| Mr. Xiao is CEO of Hermed Capital, a VC fund focusing on healthcare industry investment. Previously, Mr. Xiao held various senior positions at Fosun Pharma, including Business Development Head, Deputy Chief of the IPO team for Fosun Pharma Listing in Hong Kong Exchange, and Vice General Manager of the Technological Center. At his last position with Fosun Pharma Technological Center, Mr. Xiao was responsible for evaluating new technology, R&D and investment. He reviewed more than 150 projects annually. Mr. Xiao also served as a board member of Fosun Pharma (new drug development), Henlius (Biosimilar, antibody) and BeyondSpring, helping with financing and technology transfer. |
|
| Mr. Xiao holds a Ph.D. in Pharmacology and is a member of Bio China Advisor Committee. He finished his postdoctoral training in Rochester University, during which he co-founded a pharmaceutical company with Dr. Paul Okunieff, and won STTR support from the US government. |
|
|
|
|
|
 |
| Grace Xu |
|
|
| SVP for Biomedicine Business, SanPower; Chairwoman, Denderon Corporation |
| |
| As Dendreon Chairwoman and Sanpower Group’s Senior Vice President, Ms. Xu is responsible for setting corporate strategy for the healthcare sector, and prioritizing future M&A focus. She has 25 years of experience in the Pharmaceutical and Biotech industry, and has served for many leading global companies including Novartis, AstraZeneca, and BMS. Ms. Xu has capabilities and experiences in general management, corporate strategy planning, business development, M&A, and new product planning. She also has extensive international experience in the US, Europe, Middle East and Asia. |
| |
| Ms. Xu has an MBA from Rotterdam School of Management and an MS from University of Connecticut. |
|
|
|
|
|
 |
| Jiang Zhang |
|
|
| Managing Director, Ping An Venture |
| |
| Mr. Zhang’s expertise covers several sectors including healthcare and fintech. He participated in developing innovation strategy for Ping An Ventures and executing strategic acquisitions. Before joining Ping An Ventures, Mr. Zhang worked as Strategy Consultant in McKinsey & Company, where he was responsible for strategic consulting for healthcare and financial sectors. He had worked for Philips Healthcare (Netherland), where he was engaged in product development and marketing. |
|
| Mr. Zhang received his an MBA from INSEAD and a Doctor of Computer Engineering degree from Eindhoven University of Technology. |
|
|
|
|
|
 |
| Lily Zhang |
|
|
| Partner, CDH Venture |
| |
| Lily Zhang is Partner at CDH Venture, one of the largest Private Equity Investment firms in China, with asset under management of $120 Billion RMB. Before joining CDH, Ms. Zhang worked in several renowned multinational corporations, including serving as Business Development and Information Director at GlaxoSmithKline China, and being in charge of Asian M&A and licensing program at Johnson & Johnson. |
|
|
|
|
|
 |
| Frank Zhang |
|
|
| CEO, GenScript Biotech Corporation; Chairman, Nanjing Legend |
| |
| Dr. Zhang is the co-founder and CEO of GenScript. He is also the Chairman of Nanjing Legend Biotech which is focused on CART cell therapy. Before founding GenScript, Dr. Zhang was a principal investigator at Schering-Plough from 1995 to 2002. He led drug discovery efforts in different areas including oncology, cardiovascular, and central nervous systems. His group identified the unknown drug target for a multibillion dollar drug Clopidegrel. His scientific achievement was recognized by Schering-Plough with a Presidential Award. Dr. Zhang was the first person to clone human geranylgeranyl transferase, an enzyme playing an important role in oncology. He has published more than 20 articles in leading scientific journals, and is an inventor of seven patents. |
|
| Dr. Zhang earned his Ph. D. in Biochemistry from Duke University in 1995. He received an MS degree from Nanjing University in 1987 and a BS degree from Chengdu Institute of Technology in 1984. |
|
|
|
|
|
 |
| Richard Zhao |
|
|
| Chief Investment Officer & SVP, Medical Technology Division, Fosun Pharma |
| |
| Richard Zhao has 20 years of experience in M&A, Business Development and Sales & Marketing Management on both global and regional levels. Prior to joining Fosun Pharma, Mr. Zhao held various executive positions at Bayer Healthcare and Philips Healthcare, driving international business growth and expansion. He was one of the early explorers in the 1990’s to introduce multinational companies to China, and has helped many multinational companies enter and operate in China through Shanghai Free Trade Zone. |
|
| Mr. Zhao holds an MBA degree from CEIBS and received executive education (CPD) from the Wharton School of University of Pennsylvania. |
|
| Fosun Pharma is a leading Chinese healthcare company with a market size of USD $10 billion. It is engaged in research and development, production and distribution of pharmaceuticals. |
|
|
|
|
|
|
|
|
|
